by | May 28, 2024 | Publications
Infect Agent Cancer. 2024 May 27;19(1):25. doi: 10.1186/s13027-024-00587-2. ABSTRACT This paper introduces two cases of multiple myeloma, COVID-19 infection during autologous stem cell transplantation, the treatment process, and different results of the two patients,...
by | May 27, 2024 | Publications
Adv Biol (Weinh). 2024 May 26:e2300640. doi: 10.1002/adbi.202300640. Online ahead of print. ABSTRACT Multiple myeloma (MM) stands as a prevalent hematological malignancy, primarily incurable, originating from plasma cell clones. MM’s progression encompasses...
by | May 27, 2024 | Publications
Expert Rev Anticancer Ther. 2024 May 26:1-17. doi: 10.1080/14737140.2024.2344647. Online ahead of print. ABSTRACT INTRODUCTION: Modern immunotherapy approaches are revolutionizing the treatment scenario of relapsed/refractory (RR) multiple myeloma (MM) patients,...
by | May 27, 2024 | Publications
bioRxiv [Preprint]. 2024 May 17:2024.05.15.593193. doi: 10.1101/2024.05.15.593193. ABSTRACT Multiple Myeloma (MM) remains incurable despite advances in treatment options. Although tumor subtypes and specific DNA abnormalities are linked to worse prognosis, the impact...
by | May 27, 2024 | Publications
Res Pract Thromb Haemost. 2024 Apr 24;8(4):102418. doi: 10.1016/j.rpth.2024.102418. eCollection 2024 May. ABSTRACT BACKGROUND: Multiple myeloma (MM) is associated with high risk of venous thromboembolism (VTE). Anticoagulant prophylaxis is frequently recommended but...
by | May 27, 2024 | Publications
Cureus. 2024 Apr 25;16(4):e58999. doi: 10.7759/cureus.58999. eCollection 2024 Apr. ABSTRACT Introduction Multiple myeloma (MM) is a hematological disorder characterized by aberrant multiplication of malignant plasma cells in the bone marrow. The current mainstay of...
